Mats Wahlstrom - 23 May 2025 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Reporting relationship: Director
Issuer ticker: CHRS
Reported as of: 23 May 2025
Net transaction value: -$73,881
SEC form: 4
Accepted by SEC: 28 May 2025, 17:12:50 UTC
Prior SEC filing: 11 Feb 2025
Next SEC filing: 13 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Bryan McMichael, as Attorney-in-Fact for Mats Wahlstrom

Key filing fact

Mats Wahlstrom filed Form 4 for Coherus BioSciences, Inc. (CHRS) on 28 May 2025.

Key facts

This page summarizes Mats Wahlstrom's Form 4 filing for Coherus BioSciences, Inc. (CHRS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 28 May 2025, 17:12.

Change

Previous filing in this sequence was filed on 11 Feb 2025.
Current net transaction value: -$73,881.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001459154 Primary reporting owner

Wahlstrom Mats

Relationship: Director
Address: C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY
Signature: /s/ Bryan McMichael, as Attorney-in-Fact for Mats Wahlstrom
Signature date: 28 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CHRS transaction

Common Stock

Sale

Transaction value: $73,881
Shares: -99,988
Change %: -100%
Price: $0.7389
Shares after: 0
Date: 23 May 2025
Ownership: Leonard Capital, LLC
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The reported sale transactions were effected for tax planning purposes.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7362 to $0.7448, exclusive of any fees, commissions or other expenses. The Reporting Person undertakes to provide to Coherus BioSciences, Inc., any security holder of Coherus BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Footnote F3

The Reporting Person and his spouse are the members of Leonard Capital, LLC and therefore the Reporting Person may be deemed to have voting and dispositive power of shares held by Leonard Capital, LLC.